740 results
Showing 1–20 · 0.74 seconds · RSS
mAbs
Scopus
ISSN 1942-0870 · Taylor & Francis Group · 740 articles in the index
-
Journal Article
Expanding the horizons of cancer therapy with next-generation 4-1BB agonists: a review of molecular and clinical strategies to maximize efficacy and ensure safety
Driven by the substantial limitations of first generation 4–1BB agonists urelumab and utomilumab, the field has shifted toward engineering next-generation molecules with improved therapeutic windows. This review provides a comprehensive analysis of this evolution, detailing how key molecular design…
-
Journal Article
Alpseq: an open-source workflow to turbocharge nanobody discovery with high-throughput sequencing
Nanobodies have emerged as promising tools for many biotechnological applications due to their small size, high stability and remarkable binding specificity. Next-Generation Sequencing (NGS) enables deep profiling of large nanobody libraries and panning campaigns; however, the scale and diversity…
-
Journal Article
Dual agonism and selective T-cell depletion activity of a PD-1-directed antibody for treating autoimmune diseases
Precise inhibition of autoreactivity without concomitant induction of general immunosuppression is an overarching goal that remains elusive for the treatment of autoimmune diseases. PD-1 is preferentially expressed on activated T cells that drive autoimmunity. These PD-1+ T cells could serve as a…
-
Journal Article
Targeted dual selection to optimize transposon stable pool generation of multispecifics
Growing knowledge around disease states has led to opportunities within research to make designer molecules with improved specificity and broader efficacy. These next-generation molecules frequently take advantage of multispecific targeting and controlled mechanisms of action by utilizing four…
-
Journal Article
P329G-engager: a universal mix & match antibody-based adaptor platform for cancer immunotherapy
Targeting various combinations of tumor antigens and immune cell receptors is of increasing importance in antibody-based cancer immunotherapy. Here, we present a novel modular P329G-engager platform that enables rapid combination of primary tumor-targeting and secondary immune effector antibodies…
-
Journal Article
Fine-tuning affinity and spacer design enhances T cell potency in DLL3 and BCMA CAR T cells
Chimeric antigen receptor (CAR)-modified T cells have garnered substantial attention due to their clinical success, culminating in six Food and Drug Administration-approved therapies for hematological malignancies. Notably, CD19-specific CAR T cell therapies have achieved remarkable clinical…
-
Journal Article
Rapid expression of therapeutic antibodies in mammalian cells via mRNA transfection
Messenger RNA (mRNA) has emerged as a powerful tool for protein expression in clinical settings, yet its potential as a platform for biologics manufacturing remains underexplored. Here, we evaluate transient mRNA transfection in Chinese hamster ovary (CHO) cells as a rapid and versatile system for…
-
Journal Article
Beyond sequence similarity: ML-powered identification of pHLA off-targets for TCR-mimic antibodies using high throughput binding kinetics
T-cell receptor mimic (TCRm) antibodies are an emerging class of tumor-targeting agents used in advanced immunotherapies such as bispecific T-cell engagers and CAR-T cells. Unlike conventional antibodies, TCRms are designed to recognize peptide – human leukocyte antigen (pHLA) complexes that…
-
Journal Article
2025 Ginkgo Datapoints Antibody Developability Competition outcomes: limited model performance and a call for data standardization
The Ginkgo Datapoints Antibody Developability (AbDev) Competition, a blinded benchmark for developability prediction characterized entirely on a single, industrial-scale experimental platform, was conducted from September 8 to November 18, 2025. We benchmarked predictors across five biophysical…
-
Journal Article
A cell line development vector strategy for improved expression of a trispecific T-cell engager in CHO
Recent advances in trispecific antibody (trisAb) engineering offer great therapeutic potential, but achieving high product yield and quality in cell line development remains a challenge due to complex chain pairing requirements in production cell lines. In this study, three distinct expression…
-
Journal Article
Using mass spectrometry for robust identity release testing in a global quality control network
Product identity (ID) testing is a fundamental requirement in pharmaceutical quality control. Roche/Genentech has developed and established a mass spectrometry-based platform ID method for routine release testing of biologics in the global clinical and commercial quality control environment. The…
-
Journal Article
Rapid and selective characterization of antibody-drug conjugates in complex sample matrices by native affinity liquid chromatography-mass spectrometry
Antibody-drug conjugates (ADCs) and other biopharmaceuticals require robust analytical methods to assess biotransformation in biological matrices. Current approaches often require off-line enrichment and extensive chromatographic separation, limiting throughput and complicating data processing. We…
-
Journal Article
RASP: rapid antibody functional screening by pentavalent phage display
The heavy-chain antibody variable domain (VHH) is the smallest antigen-binding domain of such antibodies, which are derived from camelids. In the past three decades, VHHs, which are also called single-domain antibodies, have been extensively used to target pathogens and/or toxins. Conventional…
-
Journal Article
ASD: antigen-specific antibody database
The development of computational models addressing therapeutic antibodies faces significant challenges. Particularly, the prediction of binding affinity across a diverse set of measurements, due to the scarcity of data. A critical data element is the set of antibody–antigen interaction pairs…
-
Journal Article
Balancing the extremes for antibody developability: hydrophobic and electrostatic germline framework signatures for CDR-loop compensation
Antibody therapeutics are a rapidly growing class of biopharmaceuticals, but concerns regarding potential developability issues persist. While complementarity-determining region (CDR) loops are imperative for antigen specificity and mutations are challenging, the framework regions can be exchanged…
-
Journal Article
Overcoming claudin family homology: discovery of ARC101, a highly potent CLDN6-specific T-cell engager with a novel CD3 binder for ovarian adenocarcinoma
Claudin-6 (CLDN6) is an oncofetal tight junction protein with minimal to no expression in healthy adult tissues but aberrant upregulation in ovarian malignancies, making it an attractive tumor-selective antigen for T cell-based immunotherapy. The development of CLDN6-targeting antibodies, however…
-
Journal Article
Near pan-alphavirus neutralization by an antibody-nanobody bispecific
Alphaviruses represent a global concern, with some such as chikungunya virus currently infecting thousands in China and others such as Venezuelan equine encephalitis virus inducing neurological symptoms in 4–14% of infected individuals. A single antibody capable of protecting from all…
-
Journal Article
Predicting non-specific binding of VHHs using machine learning models with cluster-aware validation
Propensity for nonspecific binding—also known as polyreactivity—is a serious developability risk factor for biotherapeutic candidates. To minimize this risk, drug companies are increasingly relying on in silico tools utilizing machine learning methods, but developing these tools is challenging. For…